Company

LongBio Pharma Reports Positive Top-Line Phase II Data for LP-005 – Bifunctional C5/C3b Antibody Achieves 100% Hemolysis Control in PNH
Clinical trial resultsHKG: 1779

LongBio Pharma Reports Positive Top-Line Phase II Data for LP-005 – Bifunctional C5/C3b Antibody Achieves 100% Hemolysis Control in PNH

LongBio Pharma (Suzhou) Co., Ltd. (HKG: 1779) announced that top‑line data from its China Phase II clinical trial of LP‑005 have been reported, demonstrating significant efficacy together with a favorable…

European Commission Approves Merck's KEYTRUDA Plus Padcev for Resectable Muscle-Invasive Bladder Cancer – First and Only PD-1 Inhibitor–ADC Regimen for MIBC in the EU

European Commission Approves Merck’s KEYTRUDA Plus Padcev for Resectable Muscle-Invasive Bladder Cancer – First and Only PD-1 Inhibitor–ADC Regimen for MIBC in the EU

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Clinical trial approval / initiationHengrui Pharmaceuticals

Hengrui’s HRS9531 Wins NMPA Approval for CKD Trial – Dual GIPR/GLP-1R Agonist Expands Beyond Diabetes and Obesity

Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program – R&D Pipeline Optimization Ditches €3.7 Billion in Acquired Assets
ETR: MRKHengrui Pharmaceuticals

Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program – R&D Pipeline Optimization Ditches €3.7 Billion in Acquired Assets

Bristol Myers Squibb's Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis
Auto-immuneBMS

Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Day One BiopharmaceuticalsNASDAQ: DAWN

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Show More